-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653A.O2.6 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
multiple myeloma, Biological, Diseases, Therapies, CAR-Ts, Plasma Cell Disorders, immunotherapy, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies
Saturday, December 5, 2020: 9:30 AM-11:00 AM
David S. Siegel, MD, Hackensack Univ. Med. Ctr. and Sagar Lonial, MD, Emory University School of Medicine
Siegel: Takeda: Consultancy, Honoraria, Speakers Bureau; Amgen: Consultancy, Honoraria, Speakers Bureau; Merck: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; Celulatiry: Consultancy; Karyopharma: Consultancy, Honoraria.
9:30 AM

Sham Mailankody, MBBS1, Jeffrey V. Matous, MD2, Michaela Liedtke, MD3, Surbhi Sidana, MD4, Shahbaz Malik, MD5*, Rajneesh Nath, MD6, Olalekan O. Oluwole, MBBS, MPH7, Erin E. Karski8*, Wade Lovelace8*, Xiangdong Zhou, PhD8*, Srinand Nandakumar, PhD8*, Arun Balakumaran, MD, PhD8 and Parameswaran Hari, MBBS, MD9

1Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY
2Sarah Cannon Research Institute, Colorado Blood Cancer Institute, Denver, CO
3Division of Hematology, Stanford University, Stanford, CA
4Center for Cancer Cell Therapy, Stanford University, Stanford, CA
5Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
6Banner MD Anderson Cancer Center, Gilbert, AZ
7Vanderbilt Univeristy, Nashville, TN
8Allogene Therapeutics, South San Francisco, CA
9Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Brookfield, WI

9:45 AM

Melissa Alsina, MD1, Nina Shah, MD2, Noopur S. Raje, MD3, Sundar Jagannath, MD4, Deepu Madduri, MD5, Jonathan L. Kaufman, MD6, David S. Siegel, MD7, Nikhil C. Munshi, MD8, Jacalyn Rosenblatt, MD9, Yi Lin, MD, PhD10, Andrzej Jakubowiak, MD, PhD11, Jagoda Jasielec, MD11*, Alison Timm, MS12*, Ashley Turka12*, Pingping Mao, PhD12*, Nathan Martin, PhD13*, Timothy B. Campbell, MD, PhD13*, Kristen Hege13, Hans Bitter, PhD12*, Fabio Petrocca, MD12* and Jesus G. Berdeja, MD14

1Department of Blood & Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Ctr. Hematologic Malignancies Program, Tampa, FL
2Associate Professor of Medicine, University of California San Francisco, San Francisco, CA
3Massachusetts General Hospital Cancer Center, Mass General Hospital Cancer Center, Boston, MA
4Department of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY
5Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
6Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
7Hackensack Univ. Med. Ctr., Hackensack, NJ
8Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
9Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
10Division of Hematology, Mayo Clinic, Rochester, MN
11University of Chicago, Chicago, IL
12bluebird bio, Cambridge, MA
13Bristol Myers Squibb, Princeton, NJ
14Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

10:00 AM

Yi Lin, MD, PhD1, Noopur S. Raje, MD2, Jesus G. Berdeja, MD3, David S. Siegel, MD4, Sundar Jagannath, MD5, Deepu Madduri, MD5*, Michaela Liedtke, MD6, Jacalyn Rosenblatt, MD7, Marcela V. Maus, MD, PhD2, Monica Massaro, MPH8*, Fabio Petrocca, MD9*, Andrea Caia, MS10*, Zhihong Yang, PhD10*, Timothy B. Campbell, MD, PhD10*, Kristen Hege, MD10, Nikhil C. Munshi, MD11 and James N. Kochenderfer, MD12

1Mayo Clinic, Rochester, MN
2Massachusetts General Hospital Cancer Center, Boston, MA
3Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN
4Hackensack University Medical Center, Hackensack, NJ
5Mount Sinai Medical Center, New York, NY
6Stanford University Medical Center, Stanford, CA
7Beth Israel Deaconess Medical Center, Boston, MA
8bluebird bio, Inc., Cambridge, MA
9bluebird bio, Cambridge, MA
10Bristol Myers Squibb, Princeton, NJ
11Dana-Farber Cancer Institute, Boston, MA
12Surgery Branch, National Cancer Institute/National Institutes of Health, Bethesda, MD

10:15 AM

Siguo Hao, MD, PhD1*, Jie Jin, MD, PhD2, Songfu Jiang, MD3*, Zonghai Li, MD, PhD4*, Wenhao Zhang, MD, PhD1*, Min Yang, MD, PhD5*, Kang Yu, MD3*, Wei Wang, MD, PhD4*, Linjun Chen, MD, PhD1*, Haitao Meng, MD, PhD5*, Mingxia He, MD3*, Jun Xiao, MD4*, Rong Tao, MD, PhD1*, Xin Huang, MD, PhD5*, Chongyun Xing, MD3*, Daijing Yuan, MD4*, Jianbo Wan, MD, PhD1*, Shasha Wang, MD, PhD5*, Lihui Dai, BS3* and Hong Ma, MD6

1Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
2Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China
3The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4CARsgen Therapeutics Co. Ltd, Shanghai, China
5The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6CARsgen Therapeutics Corporation, Bellaire, TX

10:30 AM

Shaji K. Kumar, MD1, Rachid C. Baz, MD2, Robert Z. Orlowski, MD, PhD3, Larry D. Anderson Jr., MD, PhD4, Hong Ma, MD5, Alexandria Shrewsbury, MS2*, Katrina A. Croghan, M.S.6*, Mrinalini Bilgi, MS5*, Ankit Kansagra, MD4, Prashant Kapoor, MD1, Zonghai Li, MD, PhD7* and Jason Brayer, PhD, MD2

1Mayo Clinic Rochester, Division of Hematology, Rochester, MN
2H. Lee Moffitt Cancer Center, Tampa, FL
3Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX
4Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX
5CARsgen Therapeutics Corporation, Bellaire, TX
6Division of Hematology, Mayo Clinic, Rochester, MN
7CARsgen Therapeutics Co. Ltd, Shanghai, China

10:45 AM

Caitlin L. Costello, MD1, Adam D. Cohen, MD2, Krina K. Patel, M.D.3, Syed S Ali, MD4, Jesus G. Berdeja, MD5, Nina Shah, MD6, Siddhartha Ganguly, MD7*, Mehmet Hakan Kocoglu, MD8, Mehrdad Abedi, MD9, Eric M. Ostertag, MD, PhD10*, Chris E Martin, Ph.D.10*, Majid Ghoddussi, Ph.D.11*, Devon J Shedlock, PhD10, Joanne McCaigue, M.S.11*, Hamid Namini, Ph.D.11*, Sreeni Yalamanchili11*, Matthew A. Spear, MD11 and Tara K. Gregory, MD12*

1Moores Cancer Center, University of California, San Diego, La Jolla, CA
2University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA
3Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
4Hematology, John Hopkins University, Baltimore, MD
5Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN
6Associate Professor of Medicine, University of California San Francisco, San Francisco, CA
7The University of Kansas Cancer Center, Fairway, KS
8Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
9University of California Davis, Sacramento, CA
10Poseida Therapeutics, Inc., San Diego, CA
11Poseida Therapeutics, San Diego, CA
12Sarah Cannon Research Institute, Nashville, TN

*signifies non-member of ASH